Sabatini Brent 4
4 · Vir Biotechnology, Inc. · Filed Jun 2, 2026
Research Summary
AI-generated summary of this filing
Vir Biotechnology (VIR) SVP Brent Sabatini Sells 379 Shares
What Happened
Brent Sabatini, SVP and Chief Accounting Officer at Vir Biotechnology, sold 379 shares of VIR common stock on June 1, 2026. The shares were disposed at $9.45 per share for a total transaction value of $3,582. The sale was executed under a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction date and price: 2026-06-01 — 379 shares at $9.45/share (total $3,582).
- Transaction type/code: Sale (S) — open market or private sale.
- Filing/timeliness: Report filed 2026-06-02 for a 2026-06-01 transaction (not flagged as late).
- Shares owned after transaction: Not specified in the Form 4.
- Footnotes: F1 — sale effected pursuant to a 10b5-1 plan adopted Dec 19, 2025. F2 — the 379 shares were acquired May 29, 2026 under an employee stock purchase program (ESPP).
Context
A sale under a Rule 10b5-1 plan typically reflects a prearranged disposition and is often routine rather than an immediate signal about company prospects. The dollar value here ($3.6k) is small, so this single transaction is unlikely to be material for most investors.
Insider Transaction Report
Form 4
Sabatini Brent
SVP, Chief Accounting Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-06-01$9.45/sh−379$3,582→ 61,902 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
- [F2]Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program.
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact|2026-06-02